| Authors | Howard, ME. Piper, AJ. Stevens, B. Holland, AE. Yee, BJ. Dabscheck, E. Mortimer, M. Burge, AT. Flunt, D. Buchan, C. Rautela, L. Sheers, N. Hillman, D. Berlowitz, DJ. |
|---|---|
| Type | Journal Article (Original Research) |
| Journal | Thorax |
| PubMed ID | 27852952 |
| Year of Publication | 2017 |
| URL | http://thorax.bmj.com/content/early/2016/11/15/thoraxjnl-2016-208559.full |
| DOI | http://dx.doi.org/10.1136/thoraxjnl-2016-208559 |
| Download |  2017_May_Howard_CPAP_vs_NIV_Thorax.pdf (852.9 KB) |
| Abstract | BACKGROUND: Obesity hypoventilation syndrome (OHS) is the most common indication for home ventilation, although the optimal therapy remains unclear, particularly for severe disease. We compared Bi-level and continuous positive airways pressure (Bi-level positive airway pressure (PAP); CPAP) for treatment of severe OHS. METHODS: We conducted a multicentre, parallel, double-blind trial for initial treatment of OHS, with participants randomised to nocturnal Bi-level PAP or CPAP for 3 months. The primary outcome was frequency of treatment failure (hospital admission, persistent ventilatory failure or non-adherence); secondary outcomes included health-related quality of life (HRQoL) and sleepiness. RESULTS: Sixty participants were randomised; 57 completed follow-up and were included in analysis (mean age 53 years, body mass index 55 kg/m2, PaCO2 60 mm Hg). There was no difference in treatment failure between groups (Bi-level PAP, 14.8% vs CPAP, 13.3%, p=0.87). Treatment adherence and wake PaCO2 were similar after 3 months (5.3 hours/night Bi-level PAP, 5.0 hours/night CPAP, p=0.62; PaCO2 44.2 and 45.9 mm Hg, respectively, p=0.60). Between-group differences in improvement in sleepiness (Epworth Sleepiness Scale 0.3 (95% CI -2.8, 3.4), p=0.86) and HRQoL (Short Form (SF)36-SF6d 0.025 (95% CI -0.039, 0.088), p=0.45) were not significant. Baseline severity of ventilatory failure (PaCO2) was the only significant predictor of persistent ventilatory failure at 3 months (OR 2.3, p=0.03). CONCLUSIONS: In newly diagnosed severe OHS, Bi-level PAP and CPAP resulted in similar improvements in ventilatory failure, HRQoL and adherence. Baseline PaCO2 predicted persistent ventilatory failure on treatment. Long-term studies are required to determine whether these treatments have different cost-effectiveness or impact on mortality. TRIAL REGISTRATION NUMBER: ACTRN12611000874910, results. |
http://www.ibas.org.au/what-we-do/publications/3872880
SHIFT WORK AND BREASTFEEDING PROJECT
Researchers at Austin Health are looking for volunteers to participate in a study exploring the impact shift work has on breast milk composition. Participants will be compensated with a $100 gift voucher.
Interstitial lung disease (ILD) is a chronic lung condition that causes stiff lungs and restricts sufferers from taking a deep breath. Exercise in a gym, or swimming, walking or riding a bike, can help...
HEALTHY MALES AND FEMALES WANTED FOR SLEEP STUDY
Interested to participate in a study investigating the effect of fatigue on driving performance?
A/PROF MARK HOWARD AWARDED MAJOR COMPETITIVE MRFF GRANT
IBAS leads project to revolutionize Home Ventilation with $1.2 million grant for Assoc. Prof Mark Howard's research titled "Synchronise non-invasive ventilation at home".
PROF ANNE HOLLAND RECEIVES PRESTIGIOUS RESEARCH AWARD
Prof Anne Holland receives prestigious award for Excellent in Research Engagement and Impact from Monash University.
WORLD SLEEP DAY ON 17TH MARCH 2023
The benefits of quality sleep and to acknowledge the issue of sleep problems and their medical, educational, and social aspects as well as the prevention and management of sleep disorders, is promoted on World Sleep Day on the 17th March 2023.
A/PROF MARK HOWARD IS LISTED IN 'THE AUSTRALIAN'
The Australian's Research magazine names the top researcher and top research institution in each field of research, based on the number of citations for papers published in the top 20 journals in each field over the past five years.
© 2024 Institute for Breathing and Sleep. All Rights Reserved. ABN 39 093 685 879
Powered by Helmut Design | Manage
